Equities research analysts predict that VBI Vaccines Inc. (NASDAQ:VBIV) will report earnings per share of ($0.07) for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for VBI Vaccines’ earnings, with estimates ranging from ($0.09) to ($0.05). VBI Vaccines posted earnings per share of ($0.05) during the same quarter last year, which would suggest a negative year over year growth rate of 40%. The business is scheduled to announce its next quarterly earnings report on Wednesday, May 5th.
On average, analysts expect that VBI Vaccines will report full year earnings of ($0.27) per share for the current financial year, with EPS estimates ranging from ($0.33) to ($0.24). For the next year, analysts forecast that the business will post earnings of ($0.13) per share, with EPS estimates ranging from ($0.29) to $0.05. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that cover VBI Vaccines.
VBI Vaccines (NASDAQ:VBIV) last issued its quarterly earnings data on Monday, March 1st. The biopharmaceutical company reported ($0.06) earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The business had revenue of $0.16 million during the quarter, compared to analysts’ expectations of $0.44 million. VBI Vaccines had a negative return on equity of 36.69% and a negative net margin of 2,837.73%.
VBIV has been the subject of several recent analyst reports. Jefferies Financial Group initiated coverage on VBI Vaccines in a research note on Thursday, February 25th. They issued a “buy” rating and a $7.00 price target for the company. Zacks Investment Research lowered VBI Vaccines from a “hold” rating to a “sell” rating in a research note on Saturday, March 6th. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $5.90.
A number of large investors have recently bought and sold shares of the business. tru Independence LLC purchased a new stake in shares of VBI Vaccines in the fourth quarter valued at approximately $2,782,000. BlackRock Inc. grew its position in shares of VBI Vaccines by 7.8% in the fourth quarter. BlackRock Inc. now owns 13,175,944 shares of the biopharmaceutical company’s stock valued at $36,234,000 after purchasing an additional 948,860 shares in the last quarter. General American Investors Co. Inc. grew its position in shares of VBI Vaccines by 63.5% in the fourth quarter. General American Investors Co. Inc. now owns 1,635,785 shares of the biopharmaceutical company’s stock valued at $4,498,000 after purchasing an additional 635,185 shares in the last quarter. Swiss National Bank purchased a new stake in shares of VBI Vaccines in the fourth quarter valued at approximately $1,006,000. Finally, Creative Planning lifted its holdings in VBI Vaccines by 975.3% in the fourth quarter. Creative Planning now owns 352,087 shares of the biopharmaceutical company’s stock valued at $968,000 after acquiring an additional 319,344 shares during the last quarter. Institutional investors own 52.13% of the company’s stock.
Shares of VBIV stock opened at $2.94 on Wednesday. The stock has a market cap of $747.33 million, a PE ratio of -17.29 and a beta of 2.14. The business has a 50-day simple moving average of $3.06 and a 200-day simple moving average of $3.09. The company has a quick ratio of 8.95, a current ratio of 9.06 and a debt-to-equity ratio of 0.10. VBI Vaccines has a 52-week low of $1.18 and a 52-week high of $6.93.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.